Prostate Cancer Clinical Trial

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

Summary

We postulate that multiple apoptototic events are indusce through testosterone depletion and repletion with taxotere given in conjunction with androgen withdrawal.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of prostate adenocarcinoma histologically confirmed at MSKCC or SKCCC.
Patient must have a serum testosterone > 180 ng/dl.
Karnofsky performance status (KPS)>_70%.
Patients must have adequate organ function as defined by the following
laboratory criteria:
WBC >_ 3500/mm3
ANC >_1500/mm3
Platelet count >100,000/mm3
Hemoglobin >8.0g/dL
Creatinine <1.6mg/dl
Total Bilirubin WNL (unless due to Gilbert's disease and other LFTs are WNL)
SGOT and SGPT If alkaline phosphatase is _< 2.5 x ULN, any elevations in
AST/ALT; OR if AST/ALT is _<1.5 x ULN, any elevation in alkaline phos

Prior hormonal therapy is allowed as:

Neoadjuvant treatment prior to radiation therapy or radical pmstatectomy, provided that the total duration of therapy does not exceed 6 months (Proscar is not considered a hormone therapy).
One cycle of intermittent therapy up to a maximum exposure of 6 months (Proscar is not considered a hormone therapy).
Patients must be at least 18 years of age.
Patients must have signed an informed consent document stating that they understand the investigational nature of the proposed treatment

Exclusion Criteria:

Clinically significant cardiac disease (New York Heart Association Class III/IV), or severe debilitating pulmonary disease.
Uncontrolled serious active infection.
Anticipated survival of less than 3 months.
Active CNS or epiduraltumor
Inability or unwillingness to comply with the treatment protocol, follow-up, or research tests
Peripheral neuropathy >_ grade 3.
Patients with a history of severe hypersensitivity reaction to drugs formulated with polysorbate 80.
Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 6 months after completion of the treatment.
Prior chemotherapy
Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, St. Johns's Wort (hypericum perforatum) and ketoconazole is prohibited.

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

102

Study ID:

NCT00587431

Recruitment Status:

Completed

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

102

Study ID:

NCT00587431

Recruitment Status:

Completed

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider